Patent ID: 11944689
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 16:
17. The Ligand Drug Conjugate compound of claim 16 wherein the compound is represented by the structure of:, or pharmaceutically acceptable salt(s) thereof, wherein
subscript a is 1 so that A is present, wherein A is an alpha-amino, beta-amino or another amine-containing acid residue;
Ra3 is —H, optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), —RPEG1—O—(CH2CH2O)n′—RPEG2;
RPEG1 is C4 alkylene;
RPEG2 is —H or C1-C4 alkyl;
subscript n′ ranges from 1 to 36; and
wherein the basic nitrogen atom bonded to Ra3 is optionally protonated;
R19B is —CH(CH3)—CH(OH)-Ph, —CH(CO2H)—CH(OH)—CH3, or —CH(CO2H)—CH2Ph;
R34 is isopropyl; and
R35 is methyl or —(CH2)3NH(C═O)NH2,, or
wherein the compound is represented by the structure of:, or pharmaceutically acceptable salt(s) thereof, wherein
subscript a is 1, so that A is present, wherein A is an alpha-amino, beta-amino or another amine-containing acid residue;
Ra3 is —H, optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), —RPEG1—O—(CH2CH2O)n′—RPEG2;
RPEG1 is C4 alkylene;
RPEG2 is —H or C1-C4 alkyl;
subscript n′ ranges from 1 to 36; and
wherein the basic nitrogen bonded to Ra3 is optionally protonated; and
R19B is —CH(CH3)—CH(OH)-Ph, —CH(CO2H)—CH(OH)—CH3, or —CH(CO2H)—CH2Ph.